Orexigen Therapeutics, Third Phase III Trial for Contrave to Treat Obesity

Oct 17, 2007 - Orexigen™ Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders including obesity, announced the initiation of the third trial in its Phase III clinical trial program for its lead product candidate Contrave™ as a treatment for obesity. The program includes a set of four Phase III trials evaluating a variety of obesity-related outcome measures... Orexigen Therapeutics' Press Release-